Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 281articles · 30d
- 6+ hour agolatest article
- Aug 17, 2026earliest in window
- 91%with images
- 289avg words
- Economy, Business & Finance 160
- Health & Wellness 129
- Medical 128
- Business & Industrial 117
- Finance & Business 105
- Health 59
- Science & Technology 48
- Science & Nature 33
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
TAGRISSO?? (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
11+ hour, 37+ min ago (605+ words) Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages These results were presented today during the Presidential…...
NYU Langone Health's Perlmutter Cancer Center Appoints New Vice Chair of Physics and Dosimetry in the Department of Radiation Oncology
3+ day, 8+ hour ago (183+ words) NEW YORK, Sept. 10, 2026 /PRNewswire/ -- NYU Langone Health's Perlmutter Cancer Center has appointed Sean L. Berry, PhD, as vice chair of physics and dosimetry in the Department of Radiation Oncology. Dr. Berry brings more than 20 years of experience in radiation oncology physics,…...
Immuno-Oncology Pioneer Dr. Michael Kalos Joins Kos Biotechnology Partners as Venture Partner
3+ day, 9+ hour ago (313+ words) NEW YORK and ATHENS, Greece, Sept. 10, 2026 /PRNewswire/ -- Kos Biotechnology Partners, a global life sciences investment firm, today announced the appointment of renowned immuno-oncology leader Michael Kalos, PhD, as Venture Partner. Dr. Kalos brings decades of biopharmaceutical executive leadership, drug discovery,…...
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
3+ day, 9+ hour ago (346+ words) Despite advances in care, most patients with FL eventually experience relapse, highlighting the need for additional treatment options across multiple lines of therapy.3 The acceptance of cancer therapies such as MINJUVI® in the treatment of FL represents a significant step,…...
Olympus Announces New Class of iTind™ Center of Excellence Program Physicians
3+ day, 9+ hour ago (457+ words) Program Aims to Advance Minimally Invasive Treatment of Enlarged Prostate CENTER VALLEY, Pa., Sept. 10, 2026 /PRNewswire/ -- Olympus Corp. of the Americas (Olympus) is pleased to announce the newest members of the iTind™ Center of Excellence (COE) Program, which is designed to…...
Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline
4+ day, 1+ hour ago (429+ words) BioSpace Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline CAMBRIDGE, England--(BUSINESS WIRE)--Clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as Chief…...
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
3+ day, 20+ hour ago (140+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
3+ day, 21+ hour ago (194+ words) BioSpace Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief…...
Community Clinical Research Joins PhaseWell Research to Anchor Inpatient CNS Capabilities and Expand Clinical Trial Access Across Austin and Broader Texas Region
3+ day, 22+ hour ago (768+ words) BioSpace Community Clinical Research Joins PhaseWell Research to Anchor Inpatient CNS Capabilities and Expand Clinical Trial Access Across Austin and Broader Texas Region The partnership establishes Community Clinical Research as the foundation of PhaseWell’s inpatient neuropsychiatric research capabilities, deepening the…...
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie
3+ day, 22+ hour ago (265+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...